News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
Hyfe is delighted to announce that our category-defining cough-monitoring technology is now available on Actigraph’s LEAP wearable for use in clinical trials (press release).
This partnership advances research by enabling the collection of accurate, continuous cough frequency data on Actigraph’s FDA-cleared medical-grade LEAP wearable alongside digital measures including heart rate, sleep, movement, and oxygen saturation. The Hyfe cough algorithms, widely used in more than 50 studies to date, provide a timestamp of each cough with millisecond accuracy, enabling detailed analysis of cough rates and bouts. Via this partnership, composite metrics, where cough is analysed alongside other digital biomarkers, will be available for the first time.
Cough is an important symptom across many therapeutic areas including COPD, asthma, IPF/ILD and chronic cough, yet it has historically been difficult to measure which has limited its utility as a biomarker in clinical trials. Traditional approaches, such as patient-reported outcomes or short-term audio recordings (typically maximum 24h or limited to nighttime), have provided incomplete data, hindering insights into disease progression and treatment efficacy. Cough has been shown to be highly variable day-to-day (ref), meaning long-term monitoring is critical to accurately assess cough trends. For long-term monitoring to be acceptable to patients, it has to be passive and privacy-preserving.
Hyfe’s validated technology addresses these challenges by offering AI-powered continuous cough monitoring. Hyfe’s research tools have been used in dozens of investigator-initiated and sponsor-led studies, from proof-of-concepts to Phase 2b trials, to real-world-evidence studies. This partnership with Actigraph makes long-term cough-monitoring even more widely available.
The integration of Hyfe’s algorithms with ActiGraph’s LEAP wearable creates a comprehensive digital health solution for clinical trial sponsors, CROs, and researchers. This partnership allows:
Hyfe’s technology remains available directly to sponsors conducting cough-focused studies, ensuring that researchers retain access to cutting-edge solutions tailored to their needs. This partnership further extends the reach of Hyfe’s technology, making it easier to incorporate into clinical trials in a wide variety of indications.
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.